Clinicopathological significance of heparanase and basic fibroblast growth factor expression in human esophageal cancer

Table 1 Expression of Hps, bFGF, MVD in esophageal carcinoma and normal esophageal tissue.

Type	n	Heparanase-positive (%)	bFGF-positivity (%)	MVD
Esophageal		52	57
carcinoma	79	(65.8)	(72.2)	30.59±13.38
Normal esophageal tissue	19	0	3 (15.8)	13.82±4.16

Table 2 Expression of Hps, bFGF, MVD in esophageal carcinoma.

Parameter	n	Hps			bFGF			MVD
		+	Positiveratio(%)	P	+	Positiveeratio(%)	P	Mean	SD	P
Gender
Male	60	40	66.7	0.787a	43	71.7	0.864a	35.32	7.55
Female	19	12	63.2		14	73.7		37.23	4.17	0.317a
Age (yr)
<60	50	33	66	1a	35	70	0.614a	35.59	3.87	0.876a
≥60	29	19	65.5		22	75.9		36.07	6.11
Tumor cell differentiation
High	27	17	63.0	0.921a	20	74.1		33.13	7.93
Moderate	33	22	66.7		23	69.7	0.918a	31.92	5.29	0.878a
Low	19	13	68.4		14	73.7		32.52	6.17
Depth of invasion
Ti+T1+T2	28	10	35.7	0c	12	42.9	0c	23.78	4.16	0c
T3+T4	51	42	82.4		45	88.2		42.01	5.40
Lymph-node metastasis
N0	32	14	43.8	0.001c	14	43.8		31.87	7.17
N1	47	38	80.9		33	70.2	0.019b	38.44	5.74	0.051a
Clinical stages
0+I+II	38	20	60.5	0.017b	23	60.5		35.95	5.19
II+IV	41	32	70.7		34	82.9	0.026h	43.19	7.15	0.375a

Note:

^aP>0.05 no significant difference;

^cP<0.05 statistical difference;

^bP<0.001 significant difference.

Table 3 Relationship between MVD and heparanase and bFGF expression.

Parameter	Hps and bFGF	bFGF and MVD	HPS and MVD
Correlation coefficient (r)	0.553	0.687	0.760
P	0.000b	0.000b	0.000b
Remark	Significant linear correlation	Significant linear correlation	Significant linear correlation

Note: 0.01 (two-tailed); it shows that coexpression of both heparanase and bFGF was significantly correlated with MVD (^bP<0.001).

Table 4 Log-rank analysis of postoperative survival periods.

	Statistics	df	P
Log rank	19.64	2	0.0001b
Breslow	15.66	2	0.0004b
Traone-ware	17.62	2	0.0001b

^bP<0.001 significant difference.

Table 5 Variables in the equation.

Variables	P	Odds ratio 95%	CI for Exp(B)
T	0.366	1.181a	0.824-1.692
N	0.035	2.430a	1.065-5.543
BFGF	0.021	2.032a	1.111-3.716
MVD	0.047	1.038a	1.000-1.077
M	0.002	11.221a	-2.427-51.880
Hps	0.000	3.390a	2.046-5.615
Clinical stage	0.207	1.256a	0.819-1.924

Remark:

^aP>1 hazardous factor.